论文部分内容阅读
目的:探讨肾癌患者血清血管内皮生长因子(VEGF)的水平及其与临床病理分期的关系。方法:选择2013年1月至2015年1月在我院行手术治疗的肾癌患者56例为观察组,选择同期在我院进行健康体检的正常成人50例作为对照,所有患者的诊断均经病理切片证实,对所有研究对象,采集其清晨空腹静脉血,用酶联免疫吸附法(ELISA)检测血清中的VEGF和VEGF受体-1(VEGFR-1)。结果:观察组血清中VEGF和VEGFR-1的浓度分别为(132.75±68.31)ng/mL和(33.76±15.39)ng/mL,均显著高于对照组,差异有统计学差异(均P<0.05);不同分期患者血清中VEGF和VEGFR-1浓度差异有统计学意义(均P<0.05),病理分期增加,VEGF与VEGFR-1的浓度增加,VEGF与VEGFR-1呈正相关(r=0.625,P<0.05)。结论:血清VEGF水平可用于诊断RCC,且对于预判RCC的病例分期具有重要价值。
Objective: To investigate the serum level of vascular endothelial growth factor (VEGF) in renal cell carcinoma and its relationship with clinical stage. Methods: Fifty-six patients with renal cell carcinoma undergoing surgery in our hospital from January 2013 to January 2015 were selected as the observation group. Fifty normal adults who underwent physical examination in our hospital during the same period were selected as controls. All patients were diagnosed Pathological examination confirmed that for all subjects, fasting venous blood samples were collected and serum VEGF and VEGF receptor-1 (VEGFR-1) were detected by enzyme linked immunosorbent assay (ELISA). Results: The serum levels of VEGF and VEGFR-1 in the observation group were (132.75 ± 68.31) ng / mL and (33.76 ± 15.39) ng / mL, respectively, which were significantly higher than those in the control group ). The levels of VEGF and VEGFR-1 in serum of patients with different stages were significantly different (all P <0.05), the pathological stage was increased, the concentrations of VEGF and VEGFR-1 were increased, VEGF and VEGFR-1 were positively correlated P <0.05). Conclusion: Serum VEGF level can be used to diagnose RCC, and it is of great value in predicting the staging of RCC.